What is Synchron?
Synchron, Inc. is a specialized neurovascular bioelectronics company focused on developing bloodstream-enabled solutions for complex nervous system disorders. Its flagship technology, the Stentrode, represents a breakthrough in motor neuroprosthetics, functioning as a brain-computer interface designed to restore functional independence to paralyzed patients. Beyond its primary application, the company is actively researching endovascular neuromodulation for conditions such as Parkinson's disease, epilepsy, depression, and hypertension. Headquartered in Silicon Valley with research facilities in Melbourne, Australia, Synchron operates at the intersection of biotechnology and advanced engineering, effectively bridging the gap between clinical research and scalable medical device manufacturing.
How much funding has Synchron raised?
Synchron has raised a total of $50M across 2 funding rounds:
Series A
$10M
Series B
$40M
Series A (2017): $10M with participation from Defense Advanced Research Projects Agency and U.S. Department of Defense
Series B (2021): $40M led by ID8 Investments, General Advance, Shanda Group, Forepont Capital Partners, and Khosla Ventures
Key Investors in Synchron
Shanda Group
Shanda Group is a global privately-owned investment group with a strong sector focus in leading edge technology and healthcare.
Forepont Capital Partners
Forepont Capital Partners is a global asset manager specializing in healthcare and life sciences, investing in biotech, medtech, and e-health start-ups.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies across health, AI, and robotics.
What's next for Synchron?
With this major enterprise-level funding, Synchron is well-positioned to accelerate its clinical trial programs and expand its R&D capabilities. The strategic focus will likely center on scaling the manufacturing of the Stentrode and navigating the regulatory pathways required for broader commercial adoption. As the company transitions from a research-heavy entity to a clinical-stage leader, the integration of its neuromodulation platform into standard medical practice remains the primary objective. Investors are closely monitoring the company's ability to translate its technological breakthroughs into tangible patient outcomes, which will be the key determinant for future valuation growth and potential market expansion in the global neurotech landscape.
See full Synchron company page
